Followers | 24 |
Posts | 2284 |
Boards Moderated | 0 |
Alias Born | 03/18/2013 |
Wednesday, July 25, 2018 12:10:33 PM
FWIW, thanks Kiwi, doing this has opened my eyes. Additionally, pre-Vascepa my Total Cholesteral was 213.
Table: Only documented Blood test is from May 2016
Mine/ Standard
>Cholesterol 188/ <199
>Triglycerides 186/ <149
>Cholesterol/HDL 3.9/ <4.9
>HDL 48/ >40
>Non-HDL 140/ <159
>LDL 103/ <129
>VLDL 37/ <29
>Calcium 9.1 8.3 - 10.4
>Blood Pressure resting/normal = 122
>Pulse rate.... depends if the nurse is pretty..... :D) 68-76
>BMI; Here's the scary one... Body Mass Index = 32.1, yikes, I've got a paunch but not an over the belt hanging gut like I swallowed a Beach ball.....
>Exercise? No, I do walk about 2-3 miles a day walking to and from my office. 10,000 steps? 2 miles is approx. 3500 steps, so, no I'm not getting the minimum daily exercise.
>Don't smoke, drink maybe 1-2 beers per week
>Diet, I'm on the see food diet, I eat just about anything I see.... I don't restrict myself. If there's salmon I eat it, if there's a brisket I eat it, BBQ no problem. Texas diet? yes, except for the beer part.
>Not a diabetic
Now the what if's;
>Would I buy Vascepa if it wasn't covered by insurance.... (see below). Current situation is I stopped out of Vascepa when the 90 day script cost me co-pay $650 through my Obamacare provider.
>Would I buy Vascepa if it was only a 7% RRR and not covered by Insurance? No. However, it depends on how the PPS does after Reduce-It? I have few vices, I think I would pay out of pocket for Vascepa simply because what it did for me previously (story to follow).
>Conversely, would I buy Vascepa if it was 7% RRR and it was covered by Insurance? Yes.
>Reasoning; when I was taking Vascepa previously I liked the general effect it had on my physiology and mental state.
Ready for my daily story? I told this one before. I was taking Vascepa for a few years (from 2013?) before my insurance no longer covered the cost. Insurance coverage stopped in like 2014 or 2015 thereabouts, when I went on Obamacare. In April 2013, I awoke from an Anxiety attack. Terrible experience, I couldn't sleep, every time I did go back to sleep, I'd wake up 6-7 minutes later in extreme mental discomfort. It was like someone was holding my head underwater, I felt like I was drowning. Very panicky. I'd been going through some family issues, stresses that may have triggered this mental state. IMHO, I felt like had I not been taking Vascepa, things could have been very bad mentally. My family has a history with mental illness. Just this fact alone can trigger things.... Oh crap.... Anyway, that's my story. Since then, what's helped me a lot without having the benefit of Vascepa, is that I drink Kombucha (probiotics), I eat yogurt, fermented foods etc. I think the serotonin uptake through one's digestive tract helps. That's my story and I'm sticking with it.
If you want more...... I have loads.... Thanks kiwi.
Almost forgot...the 7:1 Ratio, TG/HDL 186/48 = 3.9
Don't know my EPA/AA ratio, I do eat red meat
Nuke
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM